12 Most Shorted Stocks in 2025

6. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Holders: 27

Short % of Shares Outstanding (as of February 28): ~24.2%

CRISPR Therapeutics AG (NASDAQ:CRSP) is focused on creating transformative gene-based medicines for serious human diseases. Kostas Biliouris from BMO Capital maintained a “Buy” rating on the company’s stock with a price objective of $97.00. The analyst’s rating is backed by a combination of factors demonstrating the company’s promising pipeline and strategic positioning.  Apart from the continued launch progress of CASGEVY, CRISPR Therapeutics AG (NASDAQ:CRSP) anticipates numerous key milestones across its pipeline, which include updates on its lead “in vivo,” cardiovascular programs in H1 2025.

Furthermore, the upcoming clinical data from CRISPR Therapeutics AG (NASDAQ:CRSP)’s “in vivo” cardiovascular programs, CTX310 and CTX320, can potentially fuel investor sentiment and provide substantial upside. With cash, cash equivalents, and marketable securities sitting at $1,903.8 million as of December 31, 2024, CRISPR Therapeutics AG (NASDAQ:CRSP) remains well-placed to navigate the tough biotech environment and capitalize on strategic opportunities. Furthermore, the development of CTX112 and CTX131 improves its competitive edge, making it an attractive investment opportunity, says Biliouris. Due to the company’s strong cash position, it can continue investing significantly in its R&D efforts, allowing the advancement of multiple pipeline candidates simultaneously. Furthermore, it can pursue strategic acquisitions or partnerships, enhancing the technology platform and expanding its pipeline.